Efficacy of levetiracetam on upper limb movement in multiple sclerosis patients with cerebellar signs: a multicenter double-blind, placebo-controlled, crossover study.
kinematics
levetiracetam
multiple sclerosis
rehabilitation
upper extremity
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
25
04
2020
accepted:
10
06
2020
pubmed:
20
6
2020
medline:
29
6
2021
entrez:
20
6
2020
Statut:
ppublish
Résumé
The literature provides contrasting results on the efficacy of levetiracetam (LEV) in multiple sclerosis (MS) patients with cerebellar signs. It was sought to evaluate the efficacy of LEV on upper limb movement in MS patients. In this multicenter double-blind placebo-controlled crossover study, MS patients with prevalently cerebellar signs were randomly allocated into two groups: LEV followed by placebo (group 1) or placebo followed by LEV (group 2). Clinical assessments were performed by a blinded physician at T0 (day 1), T1 (day 22), T2 (2-week wash-out period, day 35) and T3 (day 56). The primary outcome was dexterity in the arm with greater deficit, assessed by the nine-hole peg test (9HPT). Secondary clinical outcomes included responders on the 9HPT (∆9HPT >20%), tremor activity of the daily living questionnaire and self-defined upper limb impairment, through a numeric rating scale. Kinematic evaluation was performed using a digitizing tablet, providing data on normalized jerk, aiming error and centripetal acceleration. Forty-eight subjects (45.2 ± 10.4 years) were randomly allocated into two groups (n = 24 each). 9HPT significantly improved in the LEV phase in both groups (P < 0.001). The LEV treatment phase led to a significant improvement (P < 0.01) of all clinical outcomes in group 1 and in dexterity in group 2. No significant changes were reported during both placebo phases in the two groups. Considering the kinematic analysis, only normalized jerk significantly improved after treatment with LEV (T0-T1) in group 1. Levetiracetam treatment seems to be effective in improving upper limb dexterity in MS patients with cerebellar signs.
Sections du résumé
BACKGROUND AND PURPOSE
The literature provides contrasting results on the efficacy of levetiracetam (LEV) in multiple sclerosis (MS) patients with cerebellar signs. It was sought to evaluate the efficacy of LEV on upper limb movement in MS patients.
METHODS
In this multicenter double-blind placebo-controlled crossover study, MS patients with prevalently cerebellar signs were randomly allocated into two groups: LEV followed by placebo (group 1) or placebo followed by LEV (group 2). Clinical assessments were performed by a blinded physician at T0 (day 1), T1 (day 22), T2 (2-week wash-out period, day 35) and T3 (day 56). The primary outcome was dexterity in the arm with greater deficit, assessed by the nine-hole peg test (9HPT). Secondary clinical outcomes included responders on the 9HPT (∆9HPT >20%), tremor activity of the daily living questionnaire and self-defined upper limb impairment, through a numeric rating scale. Kinematic evaluation was performed using a digitizing tablet, providing data on normalized jerk, aiming error and centripetal acceleration.
RESULTS
Forty-eight subjects (45.2 ± 10.4 years) were randomly allocated into two groups (n = 24 each). 9HPT significantly improved in the LEV phase in both groups (P < 0.001). The LEV treatment phase led to a significant improvement (P < 0.01) of all clinical outcomes in group 1 and in dexterity in group 2. No significant changes were reported during both placebo phases in the two groups. Considering the kinematic analysis, only normalized jerk significantly improved after treatment with LEV (T0-T1) in group 1.
CONCLUSIONS
Levetiracetam treatment seems to be effective in improving upper limb dexterity in MS patients with cerebellar signs.
Substances chimiques
Anticonvulsants
0
Levetiracetam
44YRR34555
Piracetam
ZH516LNZ10
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2209-2216Subventions
Organisme : Italian Multiple Sclerosis Research Foundation (FISM) support
Informations de copyright
© 2020 European Academy of Neurology.
Références
Kesselring J, Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol 2005; 4: 643-652.
Deuschl G, Bain P, Brin M, Ad Hoc Scientific Committee. Consensus statement of the Movement Disorder Society on tremor. Mov Disord. 1998; 13(Suppl. 3): 2-23.
Liu X, Miall C, Aziz TZ, et al. Analysis of action tremor and impaired control of movement velocity in multiple sclerosis during visually guided wrist-tracking tasks. Mov Disord 1997; 12: 992-999.
Alusi SH, Worthington J, Glickman S, et al. Evaluation of three different ways of assessing tremor in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68: 756-760.
Alusi SH, Worthington J, Glickman S, et al. A study of tremor in multiple sclerosis. Brain 2001; 124: 720-730.
Pittock SJ, McClelland RL, Mayr WT, et al. Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population. Mov Disord 2004; 19: 1482-1485.
Erasmus LP, Sarno S, Albrecht H, et al. Measurement of ataxic symptoms with a graphic tablet: standard values in controls and validity in multiple sclerosis patients. J Neurosci Methods 2001; 108: 25-37.
Solaro C, Brichetto G, Capello E, et al. Activity, tolerability and efficacy of levetiracetam on cerebellar symptoms in multiple sclerosis patients: a pilot kinematic study. Eur J Neurol 2008; 15: 619-626.
de Sire A, Bigoni M, Priano L, et al. Constraint-induced movement therapy in multiple sclerosis: safety and three-dimensional kinematic analysis of upper limb activity. A randomized single-blind pilot study. NeuroRehabilitation 2019; 45: 247-254.
de Sire A, Mauro A, Priano L, Baudo S, Bigoni M, Solaro C. Effects of constraint-induced movement therapy on upper limb activity according to a bi-dimensional kinematic analysis in progressive multiple sclerosis patients: a randomized single-blind pilot study. Funct Neurol 2019; 34: 151-157.
Gillard M, Chatelain P, Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol 2006; 536: 102-108.
Feys P, Nagels G, Helsen WF. The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis. Mult Scler 2009; 15: 371-378.
Striano P, Coppola A, Vacca G, et al. Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study. J Neurol 2006; 253: 762-766.
Goodwin SJ, Carpenter AF. Successful treatment of paroxysmal ataxia and dysarthria in multiple sclerosis with levetiracetam. Mult Scler Relat Disord 2016; 10: 79-81.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-1452.
Solari A, Radice D, Manneschi L, Motti L, Montanari E. The multiple sclerosis functional composite: different practice effects in the three test components. J Neurol Sci 2005; 228: 71-74.
Feys P, Lamers I, Francis G, et al. The nine-hole peg test as a manual dexterity performance measure for multiple sclerosis. Mult Scler 2017; 23: 711-720.
Teulings HL, Contreras-Vidal JL, Stelmach GE, et al. Parkinsonism reduces coordination of fingers, wrist, and arm in fine motor control. Exp Neurol 1997; 146: 159-170.
Sanguineti V, Morasso PG, Baratto L, et al. Cerebellar ataxia: quantitative assessment and cybernetic interpretation. Hum Mov Sci 2003; 22: 189-205.
Barrett LE, Cano SJ, Zajicek JP, et al. Can the ABILHAND handle manual ability in MS? Mult Scler 2013; 19: 806-815.
Chen CC, Bode RK. Psychometric validation of the manual ability measure-36 (MAM-36) in patients with neurologic and musculoskeletal disorders. Arch Phys Med Rehabil 2010; 91: 414-420.